
Contents

Guest Editorials
Castaldi, P.A. (Melbourne): Prophylactic Agents for Thrombosis 1-3
Farid, Z.; Miner, W.F. and Hassan, A. (Cairo): Enteric Fever in Egypt 247-250
Gamboa, E.L. (Manila): Treatment of Typhoid Fever and Typhoid Carriers in
Southeast Asia Viewpoint from the Philippines
Hart, F.D. (London): The New Antirheumatic Drugs
Holt, R.J. (Carshalton, Surrey): New Antifungal Drugs
Lexomboon, U. and Manuwan, P. (Bangkok): Treatment of Typhoid Fever and
Typhoid Carriers in Southeast Asia Viewpoint from Thailand 243-245
Linh, N.N. and Arnold, K. (Saigon): Treatment of Typhoid Fever and Typhoid
Carriers in Southeast Asia Viewpoint from South Vietnam 241-243
Morgan, T.O. (Melbourne): Current Views on Diuretics: Their Action and Use 161-163
Neu, H.C. (New York): New Broad-Spectrum Penicillins 81-87
Evaluations on New Drugs
Brogden, R.N.; Speight, T.M. and Avery, G.S. (Auckland): Bumetanide: A Pre-
liminary Report of its Pharmacological and Therapeutic Efficacy in
Oedema 4-18
Brogden, R.N.; Speight, T.M. and Avery, G.S. (Auckland): Amoxycillin: A
Review of its Antibacterial and Pharmacokinetic Properties and Thera-
peutic Use
Brogden, R.N.; Speight, T.M. and Avery, G.S. (Auckland): Timolol: A Pre-
liminary Report of its Pharmacological Properties and Therapeutic
Efficacy in Angina and Hypertension
Brogden, R.N.; Speight, T.M. and Avery, G.S. (Auckland): Minocycline: A
Review of its Antibacterial and Pharmacokinetic Properties and Thera-
peutics Use
Brogden, R.N.; Pinder, R.M.; Sawyer, Phyllis R.; Speight, T.M. and Avery, G.S.
(Auckland): Naproxen: A Review of its Pharmacological Properties and
Therapeutic Efficacy and Use
Sawyer, Phyllis, R.; Brogden, R.N.; Pinder, R.M.; Speight, T.M. and Avery, G.S.
(Auckland): Miconazole: A Review of its Antifungal Activity and
Therapeutic Efficacy
Sawyer, Phyllis R.; Brogden, R.N.; Pinder, R.M.; Speight, T.M. and Avery, G.S.
(Auckland): Clotrimazole: A Review of its Antifungal Activity and
Therapeutic Efficacy
Review Articles
Davies, D.L. and Wilson, G.M. (Glasgow): Diuretics: Mechanism of Action and
Clinical Application
Johns, M.W. (London): Sleep and Hypnotic Drugs
Mustard, J.F. (Hamilton, Ontario) and Packham, Marian A. (Toronto): Platelets,
Thrombosis and Drugs

Practical Therapeutics	
Aquinas, Sister Mary (Hong Kong): Drug Treatment of Pulmonary Tuberculosis 364-	372
Biggs, J.S.G. (Brisbane): Vomiting in Pregnancy: Causes and Management 299-	306
Emmerson, B.T. (Brisbane): Hyperuricaemia - To Treat or Not? 141-	152
Gibbs, J.M. (Christchurch): Post-Operative Analgesia	380
Nurse, D.S. (Melbourne): Urticaria: Diagnosis and Management	298
Drug Literature Abstracts	381
Subject Indices	479





Subject Index

A	systemic therapy 9: 442-443
Amphotericin B	aspergillosis 9: 443
fungal infection 9: 401-402	candidiasis 9: 442-443
Anticholinergics	fungal endocarditis and
sleep 9: 470-471	mycetoma 9: 443
Antidepressants	vaginal infections 9: 434-438
sleep 9: 471	candidal vaginitis 9: 434-437
Antifungal drugs 9: 401-405	compared with
amphotericin B 9: 401-402	other anticandidal agents 9:
clotrimazole 9: 426-445	436–437
5-fluorocytosine 9: 404–405	trichomonal vaginitis 9: 438
imidazole derivatives 9: 402-405 miconazole 9: 407-422	toxicology studies 9: 433-434
Antihistamines	dysmorphology and reproduction 9 434
sleep 9: 470-471	toxicology, acute 9: 433
acep > 110 111	toxicology, subacute and chronic 9
R	433-434
Barbiturates	
sleep 9: 465-467	D
Benzodiazepines	Dermatophytosis
sleep 9: 467–468	clotrimazole 9: 439-440
	miconazole 9: 415-417
C	Drug reactions adverse
Candidiasis systemic	barbiturates 9: 467
clotrimazole 9: 442-443	benzodiazepines 9: 468
miconazole 9: 419-420	chloral hydrate 9: 469
Candidiasis vaginal	clotrimazole 9: 444 445
clotrimazole 9: 432-438	miconazole 9: 420-421
miconazole 9: 413-415	
Carbromal	E
sleep 9: 470	Ethchlorvynol
Chloral hydrate	sleep 9: 471
sleep 9: 469 Clotrimazole 9: 403, 426-445	F
administration 9: 445	
skin infections 9: 445	5-Fluorocytosine
vaginal infections 9: 445	fungal infections 9: 404-405 Flurazepam
antimicrobial activity 9: 426-431	sleep 9: 467-468
antiamoebal activity 9: 429	Fungal infections 9: 401 –405
antibacterial activity 9: 429	clotrimazole 9: 434-443
antifungal activity 9: 426-429	miconazole 9: 412-420
in vitro 9: 426-428	
in vivo 9: 428–429	G
antitrichomonal activity 9: 429	Glutethimide
mode of action 9: 429-430	sleep 9: 470
resistance 9: 430-431	
drug reactions, adverse 9: 444 445 local therapy 9: 444	H Hypnotic drugs 9: 464-474
systemic therapy 9: 444 -445	Hypnotic drugs 9. 404-474
pharmacokinetic studies, animal 9: 431	1
pharmacokinetic studies, human 9: 431-433	Imidazole derivatives
administration, oral 9: 432-433	fungal infections 9: 402-405
absorption 9: 432	clotrimazole 9: 403
excretion 9: 433	econazole 9: 403
metabolism 9: 432-433	levamisole 9: 402
administration, topical 9: 431-432	mebendazole 9: 402-403
therapeutic trials 9: 434 443	miconazole 9: 403
candidal paronychia 9: 441	tetramisole 9: 402
skin infections, bacterial 9: 441	thiabendazole 9: 402
skin infections, fungal 9: 438-441	tinidazole 9: 403
candidal 9: 440	Insomnia 9: 459-462
compared with	
other antifungal agents 9: 441	M Mebendazole
dermatophytosis 9: 439 440	fungal infections 9: 402-403
pityriasis versicolor 9: 441	diffini infections 2. 402 405

Methaqualone	sleep patterns, effect on 9: 465
+ diphenhydramine	toxicity 9: 467
sleep 9: 470	henzodiazepines 9: 467-468
Methyprylone	drug reactions, adverse 9: 468
sleep 9: 470	toxicity 9: 468
Miconazole 9: 403, 407-422	sleep patterns, effect on 9: 468
administration 9: 421-422	chloral hydrate 9: 469
nail infections 9: 421-422	drug reactions, adverse 9: 469
skin infections 9: 421	sleep patterns, effect on 9: 469
vaginal infections 9: 421	ethyl alcohol 9: 472
antimicrobial activity 9: 407-411	hot milk drinks 9: 472
antibacterial activity 9: 416	other non-barbiturate hypnotics 9: 469-471
antifungal activity 9: 407-409	anticholinergics 9: 470 -471
in vitro 9: 407-409	antihistamines 9: 470-471 carbromal 9: 470
in vivo 9: 409	
mode of action 9: 410	ethchlorvynol 9: 471
resistance 9: 411	glutethimide 9: 470
drug reactions, adverse 9: 420-421	methaqualone
pharmacokinetic studies 9: 411	+ diphenhydramine 9: 470 methyprylone 9: 470
administration, oral 9: 411	
application, topical 9: 411	phenothiazines 9: 471-472 insomnia 9: 459-462
therapeutic trials 9: 412-420	extrinsic factors 9: 459-460
nail infections 9: 417-419	altitude 9: 460
skin infections 9: 415-417	climate 9: 460
systemic fungal infections 9: 419-420	noise 9: 459-460
vaginal infections 9: 413-415	
candidiasis 9: 413-415	intrinsic factors 9: 460–462
compared with	age 9: 460
other agents 9: 415	cental nervous system 9: 462
toxicology studies 9: 411-412	heart disease 9: 462
dysmorphology and reproduction 9: 412	pyschiatric illnesses 9: 461-462
toxicity, acute 9: 411-412	pyschological disorders 9:
toxicity, chronic 9: 412	460-461
	management 9: 473-474
N	'electrosleep' therapy 9: 473-474
Nail infections	hypnotic drugs, use of 9: 474
candidal paronychia	re-restablishment of normal habits 9: 473
clotrimazole 9: 441	narcolepsy 9: 463-464
miconazole 9: 417-419	management 9: 475
Nitrazepam	needs 9: 456 458
sleep 9: 467-468	deprivation, effect of 9: 457-458
	deprivation of REM sleep 9: 458
	nightmares 9: 463
Phonothioring	night terrors 9: 463
Phenothiazines	management 9: 474
sleep 9: 471 -472	physiology 9: 451-455
	body function, changes in 9: 451-452
S	body function, changes in
Skin infections, bacterial	brain activity 9: 451-452
clotrimazole 9: 441	stages of sleep 9: 452
Skin infections, fungal	stages of the brain and body 9: 452-455
clotrimazole 9: 438-441	NREM sleep 9: 454
miconazole 9: 415-417	REM sleep 9: 454-455
Sleep	wakefulness 9: 453-454
enuresis 9: 463	snoring 9: 463
management 9: 475	somnambulism 9: 463
habits 9: 455-456	management 9: 474
adults 9: 456	
children 9: 456	T
hypersomnia 9: 463	Thiabendazole
management 9: 474-475	fungal infections 9: 402
	Tinea
hypnotic drugs 9: 464-474 amphetamine derivatives 9: 472	clotrimazole 9: 439-440
	miconazole 9: 416-417
antidepressants 9: 471	v
monamine oxidase inhibitors 9: 471	V
tricyclic 9: 471 barbiturates 9: 465-467	Vaginal infections
drug reactions, adverse 9: 467	clotrimazole 9: 434-438
drug reactions, adverse 9. 40/	miconazole 9: 413-415

